Navigation Links
The Market for Pancreatic Cancer Therapies Will Nearly Double to $1.3 Billion in 2022, Fueled by the Entry of Three Novel Agents
Date:5/7/2013

BURLINGTON, Mass., May 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the pancreatic cancer therapy market will nearly double to $1.3 billion in 2022, owing to the launch and rapid uptake of three high-priced agents—Celgene/Taiho's Abraxane, Onconova Therapeutics/Baxter International/SymBio Pharmaceuticals' Estybon and Merrimack Pharmaceuticals' MM-398 (a novel formulation of irinotecan). Even though these agents do not substantially improve the overall survival of pancreatic cancer patients, they will have a significant impact on current treatment.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor Pancreatic Cancer report also finds that significant commercial reward awaits developers of therapies that are more effective and better tolerated than the FOLFIRINOX regimen in this disease, as the need for efficacious, well-tolerated therapies will remain through 2022.

"There is a dire need for novel therapies to, at a minimum, match FOLFIRINOX's efficacy," said Decision Resources Analyst Orestis Mavroudis-Chocholis Ph.D. "FOLFIRINOX is reserved for young, fitter patients, who are better able to tolerate it, and is therefore prescribed to only a minority of pancreatic cancer patients who typically have rapidly progressing disease and declining performance status.  Even an agent with equal efficacy but a better safety profile will quickly become the standard of care in pancreatic cancer."

The report also finds that physicians are excited by the prospect of SPARC stromal overexpression as a predictive biomarker for response to Abraxane and hope that this could signal the start of a personalized approach to the treatment of pancreatic cancer.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CPhI China 2013 Increases Customer Content Services and Expands Thanks to a Double Digit Pharma Industry Growth Rate and a Burgeoning Generics Market
2. Hill-Rom Receives FDA 510(k) Clearance to Market MetaNeb 4.0 Airway Clearance System
3. Virogens New Business Unit, "The Cannabis Connection," to Focus on High-End Medicinal Marijuana Dispensary Niche within $15-20 Billion Legal Marijuana Market
4. Positron And Biologics Modular Enter Into Co-Marketing Agreement
5. Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
6. Virogen Announces Launch of New Business Unit, "The Cannabis Connection", and Sets Sights on $15-20 Billion Legal Marijuana Market
7. GW Pharmaceuticals Announces Pricing of Initial Public Offering on the NASDAQ Global Market
8. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
9. Thorne Research and YouCare Pharmaceutical Group Announce Joint Venture Deal to Market Nutritional Supplements in China
10. Pharmacy Automation Systems Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
11. Pharmaceutical Market: Finland, Ireland, Denmark, Belgium, Cuba, Austria & Norway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... The American Board of Family Medicine's (ABFM) Board of Directors has selected Warren ... James C. Puffer upon his retirement. Dr. Newton will serve in the position of ... end of 2018. Upon assuming the role of President and CEO on January 1, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
Breaking Medicine News(10 mins):